MARKET

CRSP

CRSP

Crispr Therapeut
NASDAQ
83.75
-0.47
-0.56%
After Hours: 84.20 +0.45 +0.54% 19:53 03/01 EST
OPEN
84.36
PREV CLOSE
84.22
HIGH
87.08
LOW
83.33
VOLUME
1.42M
TURNOVER
0
52 WEEK HIGH
91.10
52 WEEK LOW
37.55
MARKET CAP
6.72B
P/E (TTM)
-43.1924
1D
5D
1M
3M
1Y
5Y
Rocket Pharmaceuticals' Promising Path In Gene Therapy
Rocket Pharmaceuticals, Inc. Stock surged 76% post a "Buy" recommendation for RP-A501 in Danon disease. The gene therapy is targeting a rare disease without current treatments and promises significant market potential. The company's stock is up 76% since my recommendation in August. If approved, the company should qualify for a rare pediatric disease voucher.
Seeking Alpha · 2d ago
Intellia Therapeutics Is On The Move
Shares of genome editing therapy concern Intellia Therapeutics, Inc. Have move up by a third in the past month. The company has potential cures for HAE and ATTR-CM within its pipeline, but commercialization is years away. The stock is still down 10% since Bret Jensen last looked at the company in April 2023. With its stock likely to drift, the options market provides a way to generate significant returns with meaningful downside protection. Intellian is developing a CRISPR-Cas9 genome editing platform.
Seeking Alpha · 3d ago
ARK Innovation ETF Experiences Big Outflow
NASDAQ · 3d ago
Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Editas Medicine, Inc. Is gearing up for several inflection points in 2024. The most important program for Editas Medicine would be its advancement of reni-cel for the treatment of patients with severe Sickle-Cell Disease. The company owns several CRISPR Cas9 patents and can overcome competition.
Seeking Alpha · 4d ago
Crispr Therapeutics AG (CRSP) Receives a Buy from Truist Financial
TipRanks · 5d ago
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
Median annual list price for a newly launched drug in 2023 reached $300,000. Pharmaceutical companies in the U.S. Introduced new drugs last year at prices 35% higher than in 2022. The most expensive drug for consistent use was for rare diseases such as muscular dystrophy. Over half of the FDA-approved drugs targeted orphan diseases.
Benzinga · 6d ago
Weekly Report: what happened at CRSP last week (0219-0223)?
Weekly Report · 6d ago
Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD)
3 analysts have recently maintained Buy ratings on 3 stocks in the Healthcare sector. Ideaaya Biosciences, Insulet and Crispr Therapeutics AG are among the 3 stocks with bullish sentiments. The 3 stocks are being tracked by TipRanks for their insider activities.
TipRanks · 6d ago
More
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Webull offers Crispr Therapeutics AG stock information, including NASDAQ: CRSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRSP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRSP stock methods without spending real money on the virtual paper trading platform.